AVDL
Avadel Pharmaceuticals plc
$21.64
+0.00
(+0.00%)
Mkt Cap
2.12B
Volume
35,016,239
52W Range
6.38-23.57
Sector
Healthcare
Beta
1.31
EPS (TTM)
0.00
P/E Ratio
108200.00
Revenue (TTM)
248.52M
Rev Growth (5Y)
+23.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$19.91
Overvalued · Mild
8.7% above fair value
AlphaQuality · Grade · Gated
F
Stable Earnings Power
18.9 / 100 pillar composite (overridden)
Company Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 169.12M | 27.96M | 0 | 0 | 22.33M | 59.22M | 103.27M | 172.74M | 150.25M | 173.21M | 14.78M | 22.44M |
| Net Income | (48.83M) | (160.28M) | (137.46M) | (77.33M) | 7.03M | (33.23M) | (95.30M) | 67.25M | (41.28M) | 40.66M | (84.91M) | (42.92M) |
| EPS | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.66 | -1.00 | 1.00 | -2.34 | -1.69 |
| Free Cash Flow | (46.91M) | (128.51M) | (71.02M) | (77.34M) | (48.83M) | (38.35M) | (102.89M) | (37.04M) | 17.70M | 82.66M | N/A | N/A |
| FCF / Share | -0.49 | -1.60 | -1.18 | -1.32 | -0.92 | -1.03 | -2.76 | -0.92 | 0.43 | 2.04 | N/A | N/A |
| Operating CF | (46.91M) | (128.51M) | (70.30M) | (77.31M) | (48.73M) | (38.33M) | (82.72M) | 16.66M | 18.90M | 84.29M | N/A | N/A |
| Total Assets | 164.24M | 164.70M | 132.78M | 247.26M | 311.64M | 151.44M | 190.30M | 252.11M | 245.48M | 214.98M | N/A | N/A |
| Total Debt | 1.70M | 2.62M | 131.02M | 145.00M | 130.52M | 124.65M | 115.84M | 267,000 | 815,000 | 1.12M | N/A | N/A |
| Cash & Equiv | 51.37M | 31.17M | 73.98M | 50.71M | 71.72M | 9.77M | 9.32M | 16.56M | 39.22M | 65.06M | N/A | N/A |
| Book Value | 73.85M | 87.74M | (21.14M) | 78.24M | 162.27M | (29.20M) | 2.78M | 84.56M | 42.07M | 67.86M | N/A | N/A |
| Return on Equity | -0.66 | -1.83 | N/A | -0.99 | 0.04 | N/A | -34.28 | 0.80 | -0.98 | 0.60 | N/A | N/A |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.47M | 68.13M | 52.51M | 50.41M | 50.02M | 41.50M | 27.18M | 19.45M | 7.01M | 1.50M | 0 | 0 |
| Net Income | 20,000 | 9.66M | (4.92M) | (5.04M) | (2.62M) | (13.82M) | (27.34M) | (28.79M) | (36.27M) | (64.43M) | (30.78M) | (27.45M) |
| EPS | 0.00 | 0.10 | -0.05 | -0.05 | -0.03 | -0.14 | -0.30 | -0.33 | -0.41 | -0.83 | -0.48 | -0.43 |
| Free Cash Flow | 23.25M | 12.52M | (8.23M) | 7.87M | (6.89M) | (18.19M) | (29.70M) | (28.03M) | (38.23M) | (32.02M) | (30.23M) | (16.08M) |
| FCF / Share | 0.24 | 0.13 | -0.09 | 0.08 | -0.07 | -0.19 | -0.32 | -0.33 | -0.43 | -0.41 | -0.47 | -0.25 |
| Operating CF | 23.26M | 12.70M | (8.23M) | 7.87M | (6.89M) | (18.19M) | (29.70M) | (28.03M) | (38.23M) | (32.02M) | (30.23M) | (15.37M) |
| Total Assets | 199.45M | 187.16M | 167.95M | 164.24M | 158.25M | 157.52M | 167.90M | 164.70M | 203.10M | 200.98M | 140.74M | 204.13M |
| Total Debt | 37.38M | 2.73M | 2.90M | 1.70M | 1.94M | 2.17M | 2.40M | 2.62M | 55.18M | 22.12M | 155.16M | 131.02M |
| Cash & Equiv | 79.81M | 63.40M | 56.37M | 51.37M | 28.58M | 28.85M | 35.79M | 31.17M | 51.81M | 49.98M | 83.39M | 73.98M |
| Book Value | 98.22M | 90.71M | 74.07M | 73.85M | 74.66M | 70.29M | 78.38M | 87.74M | 110.15M | 143.19M | (38.17M) | (21.14M) |
| Return on Equity | 0.00 | 0.11 | -0.07 | -0.07 | -0.04 | -0.20 | -0.35 | -0.33 | -0.33 | -0.45 | N/A | N/A |
AVDL News
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Cross Above 200-Day Moving Average – What’s Next?
Form 8.3 - Avadel Pharmaceuticals plc
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Form 8.3 -Avadel Pharmaceuticals plc
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
Form 8.3 -Avadel Pharmaceuticals plc
Form 8.3 -Avadel Pharmaceuticals plc
Form 8.3 -Avadel Pharmaceuticals plc
Form 8.3 -Avadel Pharmaceuticals plc
Form 8.3 -Avadel Pharmaceuticals plc